Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692), an expanded access program was initiated.
Patients with H3 K27M-mutant gliomas who received at least prior radiation were eligible. Patients with leptomeningeal spread were excluded. All patients received open-label ONC201 orally once every week. Safety, radiographic assessments, and overall survival were regularly assessed at least every 8 weeks by investigators. As of August 2018, a total of 18 patients with H3 K27M-mutant diffuse midline glioma or DIPG were enrolled to single patient expanded access ONC201 protocols. Among the 18 patients: seven adult (> 20 years old) and seven pediatric (< 20 years old) patients initiated ONC201 with recurrent disease and four pediatric patients initiated ONC201 following radiation, but prior to disease recurrence.
Among the 14 patients with recurrent disease prior to initiation of ONC201, median progression-free survival is 14 weeks and median overall survival is 17 weeks. Three adults among the 14 recurrent patients remain on treatment progression-free with a median follow up of 49.6 (range 41–76.1) weeks. Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks. Radiographic regressions, including a complete response, were reported by investigators in a subset of patients with thalamic and pontine gliomas, along with improvements in disease-associated neurological symptoms.
The clinical outcomes and radiographic responses in these patients provide the preliminary, and initial clinical proof-of-concept for targeting H3 K27M-mutant diffuse midline glioma with ONC201, regardless of age or location, providing rationale for robust clinical testing of the agent.
KeywordsPediatric Adult Glioma DRD2 antagonist ONC201 H3 K27M Radiation Diffuse midline Diffuse intrinsic pontine
MAK has served as a consultant (medical advisory board) to Bayer over the preceding 2 years.
Research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center. The funding was provided by Oncoceutics.
Compliance with ethical standards
Conflict of interest
RST, KM, LS, MS, JEA and WO have ownership/employment relationships with Oncoceutics that develops ONC201. LS, MS, WO and MPM serves on the Board of Directors of Oncoceutics. MPM has served as a consultant to Varian, Astra-Zeneca, Celgene, Tocagen, and Abbvie.
- 4.Jones C, Karajannis MA, Jones DTW et al (2017) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-oncology 19:153–161Google Scholar
- 5.Li J, Zhu S, Kozono D et al (2014) Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 5:882–893Google Scholar
- 7.Madhukar N, Elemento O, Benes C et al (2016) D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies. Annual Meeting of the American Association for Cancer Research (AACR)Google Scholar